Back to catalog
MOTS-c Astral research vial

MOTS-c

Also known as Mitochondrial ORF 12S rRNA type-c

Mitochondrial-derived peptide — A mitochondrial-derived peptide that modulates metabolic processes, with implications for exercise metabolism observed in rodent studies.

Latest released COA: 99.61%Lyophilized powder

Available vial sizes

  • 40 mg$117.99In stock

From $117.99In stock

View purchase options

Specifications

CAS number1627580-64-6
Molecular formulaC101H152N28O22S2
Molecular weight2174.62 g/mol
FormLyophilized powder
Research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or therapeutic purposes.

Documentation

Certificates of Analysis

Batch-specific, third-party lab certificates. Each COA is published here once its lot has been tested — preview the results, then open the full PDF.

Current released record

AST-MS40-001

Dosage
40 mg
Purity
99.61%
Laboratory
ILS Laboratories
Analyzed
2026-08-06
Open source PDF

View the compound COA record →

Related

More to explore

View all

Research context

MOTS-c research, identity and references

Also known as Mitochondrial ORF 12S rRNA type-c

What is MOTS-c?

MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial 12S rRNA. Published work includes cell and animal metabolic models; those findings do not establish human safety, efficacy, or product quality.

CAS number1627580-64-6
Molecular formulaC101H152N28O22S2
Molecular weight2174.62 g/mol
SequenceMet-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg

Cell and animal study

  1. Cell and animal study

    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.

    Lee C, Zeng J, Drew BG, et al. Cell Metabolism (2015).

    Foundational study identifying MOTS-c and examining metabolic signaling in experimental models.

    PMID 25738459 · DOI 10.1016/j.cmet.2015.02.009

Scientific review

  1. Scientific review

    MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

    Zheng Y, Wei Z, Wang T, et al. Frontiers in Endocrinology (2023).

    Reviews MOTS-c biology and clearly reflects an emerging, mostly preclinical evidence base.

    PMID 36761202 · DOI 10.3389/fendo.2023.1120533

Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-08-04. How sources are selected.

Check released lot evidence →